Androgen deprivation therapy trang 1 tải miễn phí từ TAILIEUCHUNG

"Androgen deprivation therapy" trang 1 - tải miễn phí từ Tailieuchung

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan

9 37 0

A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

11 43 1

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

7 47 2

Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review

Stroke related to androgen deprivation therapy for prostate cancer: A meta-analysis and systematic review

7 41 1

$Risk of fracture in men with prostate cancer on androgen deprivation therapy: A population-based cohort study in New Zealand$

Risk of fracture in men with prostate cancer on androgen deprivation therapy: A population-based cohort study in New Zealand

10 24 1

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

9 51 1

A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy

11 26 1

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: Effects of radiation dose escalation

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: Effects of radiation dose escalation

8 23 1

Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: Study protocol for the ‘FC Prostate’ randomized controlled trial

Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: Study protocol for the ‘FC Prostate’ randomized controlled trial

10 26 1

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer

7 43 3

HoSAGE: Sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: Study protocol for a cohort trial

HoSAGE: Sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: Study protocol for a cohort trial

7 48 3

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: A case control study

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: A case control study

7 17 1

Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012

Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012

7 73 1

Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer (ENABLE study for PCa): A study protocol for a multicenter randomized phase III trial

Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer (ENABLE study for PCa): A study protocol for a multicenter randomized phase III trial

6 56 1

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

6 37 1

Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells

Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells

11 17 1

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An Italian multicenter “real life” study

8 24 1

Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: A study protocol

Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: A study protocol

12 43 1

Systemic and tumor-directed therapy for oligometastatic prostate cancer: Study protocol for a phase II trial for veterans with de novo oligometastatic disease

Systemic and tumor-directed therapy for oligometastatic prostate cancer: Study protocol for a phase II trial for veterans with de novo oligometastatic disease

6 26 1

The LACOG-0415 phase II trial: Abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

The LACOG-0415 phase II trial: Abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

8 71 0

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.